Oligonucleotide uptake in hematological tumor cells is related to cellular species and proliferation.
- Author:
Yuan-gui ZHU
1
;
Guang-sheng ZHUO
;
Zhi-zhe CHEN
;
Xiao-chun CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Biological Transport; Cell Division; physiology; Genes, bcl-2; genetics; HL-60 Cells; Humans; Leukemia; metabolism; pathology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; metabolism; pathology; Leukemia, Promyelocytic, Acute; metabolism; pathology; Leukocytes, Mononuclear; metabolism; Lymphoma, Non-Hodgkin; metabolism; pathology; Oligonucleotides, Antisense; metabolism; Thionucleotides; metabolism; Tretinoin; pharmacology; Tumor Cells, Cultured
- From: Acta Pharmaceutica Sinica 2003;38(6):401-404
- CountryChina
- Language:Chinese
-
Abstract:
AIMTo explore whether the oligonucleotide uptake in hematological tumor cells is related to cellular species and proliferation.
METHODSIntracellular mean fluorescence intensity was measured by flow cytometry.
RESULTSAfter treatment with FITC-labeled G3139 at the concentration of 0.60 mumol.L-1 for 4 h, the G3139 uptake into peripheral blood mononuclear cell and bone marrow mononuclear cell in hematological tumor patients was significantly higher than that in normal control. There was different uptake of G3139 among the malignant hematological tumor cell strains, and the uptake in cells derived from monocyte, B lymphocyte and myeloid cell was much higher than that in cells derived from T lymphocyte. After treatment with all-trans retinoic acid (ATRA), HL60 cell proliferation was markedly inhibited and the uptake of G3139 decreased significantly.
CONCLUSIONHematological tumor cells were capable of taking up oligonucleotide, and the oligonucleotide uptake in hematological tumor cells is related to its cellular species and its activation.
